Immunotherapy Company’s Q2 Revenue ‘Handily Beats’ HC Wainwright’s Projection – Streetwise Reports (registration)
|
Immunotherapy Company's Q2 Revenue 'Handily Beats' HC Wainwright's Projection
Streetwise Reports (registration) Selvaraju reminded investors of revenue expected from another corporate partnership, this one with ApolloBio, for development in China of Inovio's DNA-based, nonsurgical immunotherapy, VGX-3100. This deal "involves an upfront payment of $15M and an … |
